Teva gets U.S. FDA approval for DEGEVMA biosimilar
Teva said the U.S. FDA approved DEGEVMA (denosumab-adet), a biosimilar to Xgeva (denosumab).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.